Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03WBS
|
|||
| Drug Name |
Aryl carboxamide derivative 3
|
|||
| Synonyms |
PMID25539043-Compound-WO2011058766Example39
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
RAQUALIA PHARMA INC. YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio INOUE, Tadashi
|
|||
| Structure |
 |
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target's Patent Info | [1] | |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.